WB donations appear to be made primarily for altruistic reasons and in response to appeals for blood. Ways to build on this humanitarianism and take advantage of new communication routes, such as e-mail, need to be developed.

Strategies aimed at encouraging current donors to donate more frequently during the first year may help to establish a regular donation behaviour.

No abstract

Approval of the new anticoagulant preservative, CPDA-1, was based in part on data from human clinical trials of CPDA-1 performed by six cooperating laboratories and two blood bag manufacturers. Biochemical and red blood cell survival properties of 123 units of blood stored for 28 to 35 days in CPDA-1 (as reported by cooperating laboratories) are briefly summarized.